Insmed’s (INSM) Overweight Rating Reaffirmed at JPMorgan Chase & Co.
JPMorgan Chase & Co. reaffirmed their overweight rating on shares of Insmed (NASDAQ:INSM – Free Report) in a research note issued to investors on Monday morning, Benzinga reports. They currently have a $36.00 target price on the biopharmaceutical company’s stock. Several other equities analysts also recently issued reports on INSM. Evercore ISI upped their price […]
More Stories
Q2 2024 Earnings Estimate for Capital Power Co. Issued By Atb Cap Markets (TSE:CPX)
Capital Power Co. (TSE:CPX – Free Report) – Analysts at Atb Cap Markets decreased their Q2 2024 earnings estimates for...
Stifel Canada Weighs in on Russel Metals Inc.’s Q2 2024 Earnings (TSE:RUS)
Russel Metals Inc. (TSE:RUS – Free Report) – Investment analysts at Stifel Canada decreased their Q2 2024 earnings per share...
Wesdome Gold Mines (TSE:WDO) PT Raised to C$14.00
Wesdome Gold Mines (TSE:WDO – Free Report) had its target price upped by Canaccord Genuity Group from C$11.75 to C$14.00...
Zynex (NASDAQ:ZYXI) Releases Earnings Results, Misses Expectations By $0.04 EPS
Zynex (NASDAQ:ZYXI – Get Free Report) issued its earnings results on Thursday. The company reported $0.04 EPS for the quarter,...
Q2 2024 EPS Estimates for Ramaco Resources, Inc. (NASDAQ:METC) Decreased by Analyst
Ramaco Resources, Inc. (NASDAQ:METC – Free Report) – Research analysts at B. Riley lowered their Q2 2024 EPS estimates for...
Copa Holdings, S.A. (NYSE:CPA) Expected to Earn Q2 2024 Earnings of $3.44 Per Share
Copa Holdings, S.A. (NYSE:CPA – Free Report) – Zacks Research decreased their Q2 2024 EPS estimates for Copa in a...